Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

have been licensed to major pharmaceutical companies. Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with several pharmaceutical companies, including Boehringer Ingelheim, Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK), Mylan, UCB and Otsuka. Vectura has been included in the FTSE 250 index since 23 March 2009. For further information, please visit Vectura's website at http://www.vectura.com

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's or Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Patterson ... Inc. (Nasdaq: PDCO ), is now an ... announced acquisition of Patterson Medical by Madison Dearborn ... retain its name for a transition period before ... rehabilitation and sports medicine products.  With the focused ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... Shakti, LLC, today announced that it has changed its name ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... our transformation into a company focused on patent claim analysis ... validity." In ... the Company commenced a corporate re-branding initiative in order to ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Latanoprost Market Investigation Report 2015-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... , MONTREAL, Oct. 14 During tough economic times, ... Global Vision,s automated inspection solutions in an effort to ... products. , First Priority,s previous method of inspection ... secondary packaging. Along with manual inspection came heavy labor ...
... N.J., Oct. 14 Weekly Digest ( http://www.bullmarket.com/digest ... publication of a special report on investment opportunities in ... updated outlooks for Gilead Sciences (Nasdaq: GILD ), ... DVAX ), Hemispherx BioPharma (Amex: HEB ), ...
Cached Medicine Technology:Global Vision Helps First Priority Reduce Costs in Tough Times 2Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak 2
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... , ... Next weekend is Labor Day weekend, the last bash of the ... this year). For IT security personnel, it should also mark the perfect time to ... costly than a simple headache. , Joe Caruso, founder and CEO-CTO of Global ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... company to freely market and sell Arterosil and Arterosil HP, and that all ... LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States District ...
(Date:8/28/2015)... Richey, FL (PRWEB) , ... August 28, 2015 , ... ... many potential workers are qualified for the position they are applying for, they are ... of this, many employers are considering altering drug testing policies in order to be ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... or no protection from harmful rays emitted by the sun ... style may even risk blindness, warn scientists in Britain. ... to this radiation may severely affect the skin, eyes or ... adults often choose sunglasses purely on the basis of their ...
... invariably heavier than others. Researchers at the US ... and Prevention and the Cincinnati Children's Hospital say ... such a phenomenon. ,Other studies have already shown ... in early life. ,However, this study is ...
... can be very unhealthy for the skin. The skin absorbs ... the usage of daily makeup. Mr. Richard Bence, a biochemist, ... they get absorbed straight into the bloodstream. ,Women, across the ... best, but this excessive use is leading to a chemical pile ...
... sperms stocked by Indian sperm banks are at a ... much Islamist or Talibanized, infertile Afghan couple do scout ... ,Ironically it is perhaps the never-ending conflicts, ... to stress-related hormonal disturbances in Afghans. And such imbalances ...
... the first scientific review of a dozen patients who have ... gene therapy technique is safe and may be effective at ... patients, half of whom live on Long Island, are in ... to medicines when they signed on for the experimental therapy. ...
... study has claimed that being employed on the moon ... depression and anxiety. ,According toChester Spell, an ... Business-Camden, the lunar settlements of tomorrow - or, for ... long-term implications for the mental health of employees working ...
Cached Medicine News:Health News:Wear Protective Sunglasses, Not Just for Style 2Health News:Autism Could Be Related to Higher Level of Growth Hormones 2Health News:Make Up Unhealthy for Skin 2Health News:Afghan Couple Turn to Indian Sperm Banks for Help 2Health News:Gene Therapy for Parkinsons Disease 2
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
... Insulin-like growth factor 1 (IGF-1) is a polypeptide ... one of a number of related insulin-like growth ... approximately 50% sequence homology with proinsulin and has ... The peptide is growth hormone (GH) dependent to ...
...
Medicine Products: